TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

INVESTOR ALERT: Investigation of Corcept Therapeutics Incorporated (CORT) by Holzer & Holzer, LLC

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Holzer & Holzer, Llc
INVESTOR ALERT: Investigation of Corcept Therapeutics Incorporated (CORT) by Holzer & Holzer, LLC

Law firm Holzer & Holzer is investigating whether Corcept Therapeutics complied with federal securities laws after the company disclosed on December 31, 2025 that the FDA issued a Complete Response Letter for its relacorilant drug application for treating hypertension secondary to hypercortisolism. The stock price dropped following this announcement, and the firm is seeking investors who suffered losses.

Insights
TSLA   neutral

Mentioned in market movers list but no specific analysis provided in the article


CORT   negative

The company received a Complete Response Letter from the FDA for its drug application, which is a regulatory setback indicating the drug cannot be approved in its current form. This triggered a stock price decline and prompted a securities investigation, suggesting potential non-compliance with disclosure obligations or investor harm.